Edges in Network
| Network | GSE5851_top8000 - GSE5851 - SiGN-BN NNSR |
| Network Description | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| Node | UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 |
| Upstream (Parents) |
|---|
| (<<) ADH6 → UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 |
| (<<) UGT1A9///UGT1A6///UGT1A8 → UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 |
| (<<) UGT1A1///UGT1A4///UGT1A9///UGT1A6///UGT1A8///UGT1A10 → UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 |
| Downstream (Children) |
|---|
| UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 → UGT1A9///UGT1A6///UGT1A8 (>>) |
| UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 → ENOSF1 (>>) |
| UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 → HMGCS2 (>>) |
| UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 → UGT1A1///UGT1A4///UGT1A9///UGT1A6///UGT1A8///UGT1A10 (>>) |
| UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 → CRYGA (>>) |
| UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 → SLCO5A1 (>>) |
| UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 → TRMT2A (>>) |
| UGT1A3///UGT1A1///UGT1A4///UGT1A9///UGT1A5///UGT1A6///UGT1A7///UGT1A8///UGT1A10 → DIO3 (>>) |
